deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT01744912

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

A Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy

Sponsor: TG Therapeutics, Inc.

Conditions B-cell Lymphomas Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Marginal Zone Lymphoma Non-Hodgkins Lymphoma Small Lymphocytic Lymphoma Waldenstrom's Macroglobulinemia
Interventions Lenalidomide Ublituximab
Updated 7 times since 2017 Last updated: May 5, 2022 Started: Nov 21, 2012 Primary completion: Feb 7, 2014 Completion: Feb 7, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor's decision

Other terminated trials from TG Therapeutics, Inc.

More terminations from TG Therapeutics, Inc.

A PHASE1 clinical study on B-cell Lymphomas and Chronic Lymphocytic Leukemia, this trial is terminated or withdrawn. The trial is conducted by TG Therapeutics, Inc. and has accumulated 7 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jun 2022 · 17 months · monthly snapshotCompleted~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jun 2022 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Completed → Terminated · Phase: PHASE1_PHASE2 → PHASE1

  4. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • TG Therapeutics, Inc.
Data source: TG Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations